The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy

被引：0
|
作者：
Byung-Hoon Min
Jeong Mo Bae
Eui Jin Lee
Hong Suk Yu
Young-Ho Kim
Dong Kyung Chang
Hee Cheol Kim
Cheol Keun Park
Suk-Hee Lee
Kyoung-Mee Kim
Gyeong Hoon Kang
机构：
[1] Sungkyunkwan University School of Medicine,Departments of Medicine, Samsung Medical Center
[2] Seoul National University College of Medicine,Department of Pathology
[3] Sungkyunkwan University School of Medicine,Department of Pathology, Samsung Medical Center
[4] Sungkyunkwan University School of Medicine,Department of Surgery, Samsung Medical Center
[5] Daehang Hospital,Department of Pathology
来源：
BMC Cancer | / 11卷
关键词：
KRAS Mutation; BRAF Mutation; MGMT Methylation; Sessile Serrate Adenoma; Mucinous Histology;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy
    Min, Byung-Hoon
    Bae, Jeong Mo
    Lee, Eui Jin
    Yu, Hong Suk
    Kim, Young-Ho
    Chang, Dong Kyung
    Kim, Hee Cheol
    Park, Cheol Keun
    Lee, Suk-Hee
    Kim, Kyoung-Mee
    Kang, Gyeong Hoon
    BMC CANCER, 2011, 11
  • [2] CpG Island Methylator Phenotype May Confer a Survival Benefit From Fluoropyrimidine-Based Adjuvant Chemotherapy on Patients With Stage II or III Colorectal Carcinomas
    Sung, Young Kyung
    Min, Byung-Hoon
    Kim, Young-Ho
    Chang, Dong Kyung
    Kim, Hee Cheol
    Park, Cheol Keun
    Kim, Kyoung-Mee
    GASTROENTEROLOGY, 2010, 138 (05) : S102 - S102
  • [3] The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer
    Kim, Seong-Geun
    Hwang, Sun-Hwi
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2016, 14
  • [4] The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer
    Seong-Geun Kim
    Sun-Hwi Hwang
    World Journal of Surgical Oncology, 14
  • [5] CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer
    Chen, Kuo-Hsing
    Lin, Liang-In
    Tseng, Li-Hui
    Lin, Yu-Lin
    Liau, Jau-Yu
    Tsai, Jia-Huei
    Liang, Jin-Tung
    Lin, Been-Ren
    Cheng, Ann-Lii
    Yeh, Kun-Huei
    ONCOLOGY, 2019, 96 (03) : 156 - 163
  • [6] 5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients With CpG Island Methylator Phenotype Colorectal Cancer
    Jover, Rodrigo
    Thuy-Phuong Nguyen
    Perez-Carbonell, Lucia
    Zapater, Pedro
    Paya, Artemio
    Alenda, Cristina
    Rojas, Estefania
    Cubiella, Joaquin
    Balaguer, Francesc
    Morillas, Juan D.
    Clofent, Juan
    Bujanda, Luis
    Rene, Josep M.
    Bessa, Xavier
    Xicola, Rosa M.
    Nicolas-Perez, David
    Castells, Antoni
    Andreu, Montserrat
    Llor, Xavier
    Boland, C. Richard
    Goel, Ajay
    GASTROENTEROLOGY, 2011, 140 (04) : 1174 - 1181
  • [7] CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer
    van Rijnsoever, M
    Elsaleh, H
    Joseph, D
    McCaul, K
    Iacopetta, B
    CLINICAL CANCER RESEARCH, 2003, 9 (08) : 2898 - 2903
  • [8] Proton Pump Inhibitors and Survival in Patients With Colorectal Cancer Receiving Fluoropyrimidine-Based Chemotherapy
    Kichenadasse, Ganessan
    Miners, John O.
    Mangoni, Arduino A.
    Karapetis, Christos S.
    Hopkins, Ashley M.
    Sorich, Michael J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (09): : 1037 - +
  • [9] Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant Chemotherapy
    Custodio, Ana
    Moreno-Rubio, Juan
    Aparicio, Jorge
    Gallego-Plazas, Javier
    Yaya, Ricardo
    Maurel, Joan
    Rodriguez-Salas, Nuria
    Burgos, Emilio
    Ramos, David
    Calatrava, Ana
    Andrada, Encarna
    Diaz-Lopez, Esther
    Sanchez, Antonio
    Madero, Rosario
    Cejas, Paloma
    Feliu, Jaime
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (09) : 2226 - 2237
  • [10] Evaluation of the CpG island methylator phenotype as a predictive biomarker for adjuvant oxaliplatin-based chemotherapy in colorectal cancer.
    Shiovitz, Stacey
    Wu, Chen
    Yu, Ming
    Gourgioti, Georgia
    Raptou, Georgia
    Kotoula, Vassiliki
    Pentheroudakis, George E.
    Kalogeras, Konstantine T.
    Fountzilas, George
    Grady, William M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345